New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
10:25 EDTCVD, CVD, EBS, EBS, CI, CI, BSX, BSX, BMY, BMY, AMGN, AMGN, ABT, ABT, HNT, HNT, SHPG, SHPG, REGN, REGN, PDCO, PDCO, VRTX, VRTXJPMorgan to host a conference
32nd Annual Healthcare Conference is being held in San Francisco on January 13-16 with webcasted company presentations to begin on January 14 at 10:30 am; not all presentations may be webcasted. Webcast Link
News For CVD;PDCO;REGN;SHPG;HNT;ABT;AMGN;BMY;BSX;CI;EBS;VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
June 22, 2015
18:56 EDTCICigna/Anthem deal could leave Humana with Aetna as only suitor, Bloomberg says
Subscribe for More Information
17:04 EDTCIOn The Fly: Top stock stories for Monday
Subscribe for More Information
13:20 EDTCIOn The Fly: Top stock stories at midday
Subscribe for More Information
11:29 EDTCIAnthem says not aware of other bidders when making Cigna bid
Subscribe for More Information
11:18 EDTCIAnthem says would suspend buybacks for year with signing of Cigna deal
Anthem (ANTM) says team has worked for months evaluating "realistic" synergies of potential Cigna (CI) deal. Says $2B in synergies within two years post-close "achievable." Sees international opportunities with Cigna acquisition. Says confident on attaining financing for Cigna purchase. Says expects to suspend buybacks for the year with signing of Cigna deal, but sees maintaining dividend. Anthem does not see regulatory issues thwarting deal. Says Cigna acquisition is a strategic priority. Comments being made on Anthem's update reaffirming its commitment to its $184 per share proposal for Cigna.
10:57 EDTCIAnthem to hold a conference call
Subscribe for More Information
10:15 EDTCIAnthem repeats FY15 revenue view of about $78.5B, consensus $78.16B
Repeats FY15 revenue view $78.5B, sees revenue for a combined Anthem (ANTM)-Cigna (CI) at >$115B. Anthem sees greater than 10% accretive to adjusted EPS in first year post-close, with accretion more than doubling in year two. Assuming the transaction closes on December 31, 2016, sees $17.00+ adjusted EPS in 2018. Anthem says expects to maintain dividend payout ratio policy, committed to retaining investment grade debt ratings. Says committed to de-levering over 2-year period post-close. Says deal is "compelling" for Cigna shareholders. Says Anthem has made "good faith efforts" to engage in valuation and governance discussions with Cigna, says fully prepared to proceed immediately to finalize due diligence and merger agreement negotiations. Comments from slides that will be presented on Anthem's update reaffirming its commitment to its $184 per share proposal for Cigna.
09:14 EDTCIOn The Fly: Pre-market Movers
Subscribe for More Information
09:04 EDTBSXBoston Scientific initiates study to assess EMBLEM S-ICD
Subscribe for More Information
09:02 EDTCICigna hits fresh highs after rejecting Anthem bid
Subscribe for More Information
09:02 EDTCIAnthem reiterates commitment to $184 per share proposal for Cigna
Subscribe for More Information
09:01 EDTCIAnthem reiterates commitment to $184 per share proposal for Cigna
Subscribe for More Information
08:52 EDTBMYPortola, Bristol-Myers, and Pfizer announce results from Phase 3 ANNEXA study
Subscribe for More Information
08:16 EDTCIAnthem, Cigna deal would be negative for Catamaran, says Leerink
Subscribe for More Information
07:54 EDTCIAnthem, Cigna deal likely to be consummated, says Leerink
Subscribe for More Information
07:16 EDTCIAnthem should be bought after Cigna offer, says Stifel
After Anthem, (ANTM) offered to buy Cigna (CI) and the latter company rejected the bid, Stifel estimates that the deal would have been 10% accretive for Anthem in the first year and 20% accretive in the second year. The firm thinks that accretion from the deal will probably be higher than expected. It also recommends buying Aetna (AET) as it believes that the Anthem offer suggests that Aetna will benefit more than expected from its own deal. The firm is cautious on Humana (HUM), saying that it may lose two potential buyers in Anthem and Cigna, while Humana may retreat if Aetna does not acquire the company quickly.
06:51 EDTCIHealth insurer tie-ups could cut competition, WSJ reports
Subscribe for More Information
06:37 EDTHNT, CIHealth insurers may change policies based on King v. Burwell ruling, NYT says
Subscribe for More Information
06:03 EDTCICigna implied volatility of 37 at upper end of index
Subscribe for More Information
05:35 EDTBMYAllied-Bristol Life Sciences licenses IP from Harvard University
Allied-Bristol Life Sciences, a biopharmaceutical enterprise jointly owned by Allied Minds and Bristol-Myers Squibb, announced that it has entered into a licensing agreement with Harvard University based on research and intellectual property developed in Professor Malcolm Whitmanís lab at the Harvard School of Dental Medicine. Building on previous studies conducted with Mark Sundrud, PhD, and Anjana Rao, PhD, at Boston Childrenís Hospital, Professor Whitmanís lab, in collaboration with Professor Ralph Mazitschek, PhD, at the Center for Systems Biology at Massachusetts General Hospital, has shown that HF works through inhibition of Prolyl-tRNA synthetase, which leads to activation of an amino acid restriction response pathway. Based on this novel and differentiated mechanism, several lead molecules have been identified by the groups at HMS and MGH that have the potential to lead to effective therapy for several conditions including fibrotic and autoimmune diseases. The licensing agreement with Harvardís Office of Technology Development is among the first in a series of discovery and development projects that Allied-Bristol Life Sciences intends to pursue. The license to the technology from Professor Whitmanís lab will be held by a new ABLS subsidiary specifically formed to pursue further research and pre-clinical development of the technology and associated molecules.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use